SAN FRANCISCO--(BUSINESS WIRE)-- Presidio Pharmaceuticals, Inc. is pleased to announce that the Company's Board of Directors has appointed Dr. H. Daniel Perez to be its new President and CEO, replacing Dr. Omar Haffar, effective immediately. Dr. Haffar has led the Company's management team over the past five years after co-founding Presidio in 2006.
Dr. Perez is currently a Venture Partner at Bay City Capital and has served as their representative on the Presidio Board of Directors since 2007. He was previously President and CEO of Berlex Biosciences until it was acquired by Bayer in 2006.
Dr. Perez will work closely with the experienced management team and investors at Presidio to continue research and development efforts on the Company's novel small molecule programs directed to patients infected with Hepatitis C Virus (HCV).
Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, in-licensing, development and commercialization of novel therapeutics for hepatitis C virus (HCV). For more information, please visit our website at www.presidiopharma.com.
Presidio Pharmaceuticals, Inc.H. Daniel Perez, MD, email@example.com